1. Home
  2. XBIO vs JAGX Comparison

XBIO vs JAGX Comparison

Compare XBIO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.43

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.43

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
JAGX
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XBIO
JAGX
Price
$2.43
$1.43
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
25.0K
9.6M
Earning Date
11-13-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,858,935.00
$11,785,000.00
Revenue This Year
$1.99
$22.41
Revenue Next Year
$20.00
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
13.30
12.45
52 Week Low
$1.90
$0.64
52 Week High
$13.93
$25.75

Technical Indicators

Market Signals
Indicator
XBIO
JAGX
Relative Strength Index (RSI) 57.78 62.17
Support Level $2.20 $0.64
Resistance Level $2.31 $1.14
Average True Range (ATR) 0.10 0.18
MACD 0.05 0.03
Stochastic Oscillator 90.63 67.88

Price Performance

Historical Comparison
XBIO
JAGX

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: